Neuere #Medikamente sind nicht kosteneffektiv für die First-Line-#Diabetes-#Therapie

Costs of SGLT2 inhibitors and GLP-1 receptor agonists ‘need to be lowered substantially’ to improve health outcomes and prevent health disparities in patients with type 2 diabetes, say researchers.
— Weiterlesen www.medscape.com/viewarticle/981829